| Nome |
# |
|
Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification., file e27ce426-bf6b-2581-e053-d805fe0acbaa
|
2.529
|
|
Diagnosi e terapia del carcinoma corticosurrenalico, file e27ce429-8a4b-2581-e053-d805fe0acbaa
|
2.111
|
|
Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors., file e27ce42d-fd0e-2581-e053-d805fe0acbaa
|
1.781
|
|
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study., file e27ce428-daf8-2581-e053-d805fe0acbaa
|
1.052
|
|
Combination Chemotherapy in Advanced Adrenocortical Carcinoma., file e27ce426-d5c2-2581-e053-d805fe0acbaa
|
859
|
|
Adjuvant mitotane treatment for adrenocortical carcinoma, file e27ce428-c943-2581-e053-d805fe0acbaa
|
786
|
|
New perspectives for mitotane treatment of adrenocortical carcinoma, file e27ce431-2a78-2581-e053-d805fe0acbaa
|
762
|
|
The Reticulin Algorithm for Adrenocortical Tumor Diagnosis: A Multicentric Validation Study on 245 Unpublished Cases., file e27ce426-fbe1-2581-e053-d805fe0acbaa
|
715
|
|
Hypertension and Acromegaly, file e27ce42f-30be-2581-e053-d805fe0acbaa
|
709
|
|
Abiraterone and increased survival in metastatic prostate cancer., file e27ce428-c936-2581-e053-d805fe0acbaa
|
630
|
|
Validation of the prognostic role of the "Helsinki Score" in 225 cases of adrenocortical carcinoma, file e27ce42b-05f3-2581-e053-d805fe0acbaa
|
607
|
|
Practical treatment using mitotane for adrenocortical carcinoma., file e27ce426-f6c1-2581-e053-d805fe0acbaa
|
568
|
|
AME position statement on adrenal incidentaloma., file e27ce426-da2e-2581-e053-d805fe0acbaa
|
498
|
|
Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection., file e27ce428-d354-2581-e053-d805fe0acbaa
|
491
|
|
Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas, file e27ce429-3525-2581-e053-d805fe0acbaa
|
484
|
|
Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease, file e27ce426-bc07-2581-e053-d805fe0acbaa
|
482
|
|
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients, file e27ce42f-5a62-2581-e053-d805fe0acbaa
|
477
|
|
Adrenocortical tumors with myxoid features: a distinct morphologic and phenotypical variant exhibiting malignant behavior., file e27ce426-c97f-2581-e053-d805fe0acbaa
|
472
|
|
Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE), file e27ce429-9db2-2581-e053-d805fe0acbaa
|
472
|
|
European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors, file e27ce42d-96c9-2581-e053-d805fe0acbaa
|
472
|
|
Merits and pitfalls of mifepristone in Cushing's syndrome, file e27ce426-b797-2581-e053-d805fe0acbaa
|
465
|
|
Management of adjuvant mitotane therapy following resection of adrenal cancer., file e27ce429-8e03-2581-e053-d805fe0acbaa
|
446
|
|
Autonomous hypercortisolism: definition and clinical implications, file e27ce42e-150a-2581-e053-d805fe0acbaa
|
445
|
|
Management of adrenal cancer: a 2013 update., file e27ce429-6c10-2581-e053-d805fe0acbaa
|
419
|
|
Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer, file e27ce429-8b98-2581-e053-d805fe0acbaa
|
407
|
|
microRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations, file e27ce426-f230-2581-e053-d805fe0acbaa
|
388
|
|
Adrenocortical Carcinoma with Hypercortisolism., file e27ce42d-a984-2581-e053-d805fe0acbaa
|
381
|
|
Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study., file e27ce429-7c70-2581-e053-d805fe0acbaa
|
365
|
|
Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates, file e27ce426-e474-2581-e053-d805fe0acbaa
|
354
|
|
Analysis of BCLI, N363S and ER22/23EK polymorphisms of the glucocorticoid receptor gene in adrenal incidentalomas, file e27ce42a-47fd-2581-e053-d805fe0acbaa
|
354
|
|
Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options., file e27ce42d-a4bd-2581-e053-d805fe0acbaa
|
302
|
|
Long-term follow-up in adrenal incidentalomas: an Italian Multicenter Study., file e27ce428-e8f5-2581-e053-d805fe0acbaa
|
297
|
|
Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment., file e27ce428-e708-2581-e053-d805fe0acbaa
|
284
|
|
Comparison of Two Mitotane Starting dose Regimens in Patients with Advanced Adrenocortical Carcinoma., file e27ce428-d34e-2581-e053-d805fe0acbaa
|
268
|
|
Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma., file e27ce42d-9c13-2581-e053-d805fe0acbaa
|
267
|
|
Pros and cons of dexamethasone suppression test for screening of subclinical Cushing's syndrome in patients with adrenal incidentalomas, file e27ce429-2298-2581-e053-d805fe0acbaa
|
262
|
|
Adrenal incidentalomas are tied to increased risk of diabetes: findings from a prospective study, file e27ce42e-d05a-2581-e053-d805fe0acbaa
|
260
|
|
Oncocytic Adrenocortical Tumors: Diagnostic Algorithm and Mitochondrial DNA Profile in 27 Cases., file e27ce426-dc69-2581-e053-d805fe0acbaa
|
259
|
|
Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study., file e27ce429-f70f-2581-e053-d805fe0acbaa
|
259
|
|
Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines., file e27ce426-fbe2-2581-e053-d805fe0acbaa
|
255
|
|
Treatment with 90Y/177Lu DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors, file e27ce42f-7222-2581-e053-d805fe0acbaa
|
253
|
|
Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement., file e27ce428-d364-2581-e053-d805fe0acbaa
|
244
|
|
Acromegaly is associated with increased cancer risk: a survey in Italy, file e27ce42c-8792-2581-e053-d805fe0acbaa
|
244
|
|
Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer., file e27ce426-c97c-2581-e053-d805fe0acbaa
|
243
|
|
Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma., file e27ce42d-8d6e-2581-e053-d805fe0acbaa
|
238
|
|
Novel mutation of PPOX gene in a patient with abdominal pain and syndrome of inappropriate antidiuresis., file e27ce42d-317c-2581-e053-d805fe0acbaa
|
214
|
|
Determination of salivary cortisol to assess time related changes of the adrenal response to stress in critically ill patients, file e27ce42e-e479-2581-e053-d805fe0acbaa
|
213
|
|
Dual-Energy X-ray Absorptiometry Predictors of Vertebral Deformities in Beta-Thalassemia Major, file e27ce42d-0204-2581-e053-d805fe0acbaa
|
200
|
|
18F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma., file e27ce428-d302-2581-e053-d805fe0acbaa
|
199
|
|
Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma, file e27ce42b-ab55-2581-e053-d805fe0acbaa
|
197
|
|
Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function., file e27ce428-d7ec-2581-e053-d805fe0acbaa
|
195
|
|
Palbociclib inhibits proliferation of human adrenocortical tumor cells., file e27ce42c-8031-2581-e053-d805fe0acbaa
|
193
|
|
MITOTANE LEVELS PREDICT THE OUTCOME OF PATIENTS WITH ADRENOCORTICAL CARCINOMA TREATED ADJUVANTLY FOLLOWING RADICAL RESECTION., file e27ce426-e3d4-2581-e053-d805fe0acbaa
|
192
|
|
Assessment of glucocorticoid therapy with salivary cortisol in secondary adrenal insufficiency., file e27ce429-8b1f-2581-e053-d805fe0acbaa
|
191
|
|
Cortisol secretion, bone health, and bone loss: a cross-sectional and prospective study in normal nonosteoporotic women in the early postmenopausal period., file e27ce429-7d60-2581-e053-d805fe0acbaa
|
179
|
|
Screening of Cushing's Syndrome in Outpatients with Type 2 Diabetes: Results of a Prospective Multicentric Study in Italy., file e27ce429-8b9b-2581-e053-d805fe0acbaa
|
179
|
|
Predictors of morbidity and mortality in acromegaly: an Italian survey., file e27ce426-d5c1-2581-e053-d805fe0acbaa
|
176
|
|
Insights on the natural history of adrenal incidentalomas, file e27ce42f-591a-2581-e053-d805fe0acbaa
|
172
|
|
Evaluation of midnight salivary cortisol as a predictor factor for common carotid arteries intima media thickness in patients with clinically inapparent adrenal adenomas, file e27ce427-4944-2581-e053-d805fe0acbaa
|
165
|
|
May an adrenal incidentaloma change its nature?, file e27ce431-034c-2581-e053-d805fe0acbaa
|
164
|
|
Ribonucleotide Reductase Large Subunit (RRM1) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer., file e27ce426-cfa6-2581-e053-d805fe0acbaa
|
159
|
|
Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma, file e27ce42d-6b9d-2581-e053-d805fe0acbaa
|
151
|
|
In vitro antitumor activity of progesterone in human adrenocortical carcinoma., file e27ce42d-ff83-2581-e053-d805fe0acbaa
|
151
|
|
Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†, file e27ce431-1db6-2581-e053-d805fe0acbaa
|
148
|
|
Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: A multicenter study, file e27ce42e-1f8d-2581-e053-d805fe0acbaa
|
142
|
|
Surgical remission of Cushing's syndrome reduces cardiovascular risk., file e27ce428-e205-2581-e053-d805fe0acbaa
|
133
|
|
CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma, file e27ce426-f05b-2581-e053-d805fe0acbaa
|
132
|
|
Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma, file e27ce42c-70ef-2581-e053-d805fe0acbaa
|
132
|
|
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer, file e27ce42b-baf6-2581-e053-d805fe0acbaa
|
130
|
|
Recovery of adrenal insufficiency is frequent after adjuvant mitotane therapy in patients with adrenocortical carcinoma, file e27ce430-0f44-2581-e053-d805fe0acbaa
|
127
|
|
Intermittent everolimus administration for malignant insulinoma, file e27ce427-0b63-2581-e053-d805fe0acbaa
|
123
|
|
Thyroid and colorectal cancer screening in acromegaly patients: Should it be different from that in the general population?, file e27ce431-1130-2581-e053-d805fe0acbaa
|
118
|
|
ENSAT registry-based randomized clinical trials for adrenocortical carcinoma, file e27ce431-2947-2581-e053-d805fe0acbaa
|
112
|
|
Mitotane: new facts for an old drug, file e27ce42e-ace4-2581-e053-d805fe0acbaa
|
106
|
|
PREOPERATIVE TREATMENT WITH METYRAPONE IN PATIENTS WITH CUSHING'S SYNDROME DUE TO ADRENAL ADENOMA., file e27ce42d-8d06-2581-e053-d805fe0acbaa
|
102
|
|
Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane., file e27ce42a-1a58-2581-e053-d805fe0acbaa
|
101
|
|
Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study, file e27ce42f-b58d-2581-e053-d805fe0acbaa
|
99
|
|
Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study, file e27ce431-4984-2581-e053-d805fe0acbaa
|
98
|
|
Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study., file e27ce42f-892a-2581-e053-d805fe0acbaa
|
93
|
|
Acute Primary Adrenal Insufficiency after Hip Replacement in a Patient with Acute Intermittent Porphyria., file e27ce42d-2a15-2581-e053-d805fe0acbaa
|
90
|
|
Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment, file e27ce42e-f005-2581-e053-d805fe0acbaa
|
90
|
|
Mitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma, file e27ce42f-bc48-2581-e053-d805fe0acbaa
|
90
|
|
CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells, file e27ce42c-e0c3-2581-e053-d805fe0acbaa
|
87
|
|
Is Follow-up of Adrenal Incidentalomas Always Mandatory?, file e27ce430-0c64-2581-e053-d805fe0acbaa
|
82
|
|
The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen., file e27ce42e-4e34-2581-e053-d805fe0acbaa
|
81
|
|
Patients With Lung Cancer and Coronavirus Disease 2019 Epidemic: An Experience From an Italian University Hospital, file e27ce430-eddf-2581-e053-d805fe0acbaa
|
80
|
|
What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study, file e27ce431-0138-2581-e053-d805fe0acbaa
|
77
|
|
Frequency and outcome of SARS-CoV-2 infection in patients with adrenocortical carcinoma followed at a reference center in Italy, file e27ce431-0e44-2581-e053-d805fe0acbaa
|
77
|
|
Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System, file e27ce433-7c65-2581-e053-d805fe0acbaa
|
77
|
|
Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma, file e27ce42f-e1cd-2581-e053-d805fe0acbaa
|
76
|
|
In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures☆, file e27ce42f-4f65-2581-e053-d805fe0acbaa
|
70
|
|
Cytotoxic effect of trabectedin in human adrenocortical carcinoma cell lines and primary cells, file e27ce42f-b58a-2581-e053-d805fe0acbaa
|
70
|
|
Efficacy of the EDP-M scheme plus adjunctive surgery in the management of patients with advanced adrenocortical carcinoma: The brescia experience, file e27ce42f-a8cc-2581-e053-d805fe0acbaa
|
65
|
|
Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study, file e27ce434-9db3-2581-e053-d805fe0acbaa
|
63
|
|
Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma, file e27ce426-fe0f-2581-e053-d805fe0acbaa
|
61
|
|
Unwanted hormonal and metabolic effects of postoperative adjuvant mitotane treatment for adrenocortical cancer, file e27ce431-42ac-2581-e053-d805fe0acbaa
|
57
|
|
Differential expression profiles of cell-to-matrix-related molecules in adrenal cortical tumors: Diagnostic and prognostic implications, file e27ce432-1c68-2581-e053-d805fe0acbaa
|
54
|
|
Improvement of cardiovascular risk factors after adrenalectomy in patients with adrenal tumors and subclinical Cushing's syndrome: A systematic review and meta-Analysis, file e27ce42e-4e0b-2581-e053-d805fe0acbaa
|
47
|
|
RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization, file e27ce427-0982-2581-e053-d805fe0acbaa
|
45
|
|
Progression of vertebral fractures in patients with adrenocortical carcinoma undergoing mitotane therapy, file e27ce435-523e-2581-e053-d805fe0acbaa
|
45
|
| Totale |
31.586 |